SFI
HEPA

Susquehanna Fundamental Investments’s Hepion Pharmaceuticals HEPA Stock Holding History

Susquehanna Fundamental Investments’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50
Closed -$76K – 1575
2021
Q3 		$76K Sell
50
-39
-44% -$62.4K ﹤0.01% 1638
2021
Q2 		$175K Hold
89
– – ﹤0.01% 1511
2021
Q1 		$163K Buy
+89
New +$195K ﹤0.01% 1417
2020
Q4 		– Sell
-16
Closed -$48K – 1540
2020
Q3 		$48K Buy
+16
New +$57.4K ﹤0.01% 1320

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Susquehanna Fundamental Investments's HEPA Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Hepion Pharmaceuticals (HEPA) in Q4 2021, closing a stake of 50 shares — an estimated $76K sold.

Susquehanna Fundamental Investments first reported a position in HEPA in Q3 2020 and held it in 4 quarters. The position peaked at $175K in Q2 2021. 39 funds tracked by Wall St. Rank hold HEPA as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Hepion Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 50 Hepion Pharmaceuticals shares in Q4 2021, an estimated $76K.
  • Susquehanna Fundamental Investments first reported a position in Hepion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Hepion Pharmaceuticals position peaked at $175K in Q2 2021.
  • 39 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.